Oct 26, 2025 3:05 pm EDT New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
Oct 24, 2025 4:05 am EDT New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
Oct 13, 2025 7:00 am EDT Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
Oct 1, 2025 4:30 pm EDT Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
Sep 23, 2025 7:00 am EDT Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
Sep 17, 2025 7:00 am EDT Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
Sep 9, 2025 7:00 am EDT New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
Aug 25, 2025 7:00 am EDT New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
